Scientific conference funding
This article was originally published in The Tan Sheet
Executive SummaryFDA will continue to partially support scientific conferences by awarding limited number of grants each fiscal year ranging from $1,000-$25,000 in direct costs per conference, FDA announces in June 6 Federal Register. Agency notes applications will be "reviewed and evaluated for their scientific and technical merit by an ad hoc review panel" that will consider content/subject matter of conference in relation to agency's mission, conference plan, experience of principal investigator/director. FDA requests plans address specific objectives of "Healthy People 2010"...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.